Table 1.
Clinical and pathological characteristics of patients
| CLDN1 expression | < median | > median | total | p-value*** | |||
|---|---|---|---|---|---|---|---|
| (n = 29) | (n = 29) | (n = 58) | |||||
| N | (%) | N | (%) | N | (%) | ||
| Gender | |||||||
| Male | 22 | (75.9) | 13 | (44.8) | 35 | (60.3) | 0.03 |
| Female | 7 | (24.1) | 16 | (55.2) | 23 | (39.7) | |
| Age (years), median [63] | |||||||
| ≤ 63 | 11 | (38.0) | 18 | (62.1) | 29 | (50.0) | 0.07 |
| > 63 | 18 | (62.0) | 11 | (37.9) | 29 | (50.0) | |
| Primary tumor localization | |||||||
| Right colon | 8 | (27.6) | 12 | (41.4) | 20 | (34.5) | 0.31 |
| Left colon | 20 | (68.9) | 17 | (58.6) | 37 | (63.8) | |
| Missing data | 1 | (3.4) | 0 | (0.0) | 1 | (1.7) | |
| Differentiation | |||||||
| Well | 10 | (34.5) | 8 | (27.6) | 18 | (31.0) | 0.38 |
| Moderate | 15 | (51.7) | 20 | (69.0) | 35 | (60.3) | |
| Missing data | 4 | (13.8) | 1 | (3.4) | 5 | (8.7) | |
| Synchronous | 17 | (58.6) | 24 | (82.7) | 41 | (70.7) | 0.08 |
| Metachronous | 12 | (41.4) | 5 | (17.3) | 17 | (29.3) | |
| Chemotherapy regimen | |||||||
| FOLFIRI | 5 | (17.3) | 8 | (27.6) | 13 | (22.4) | 0.58 |
| FOLFOX | 13 | (44.8) | 10 | (34.5) | 23 | (39.7) | |
| FOLFIRINOX | 11 | (37.9) | 11 | (37.9) | 22 | (37.9) | |
| Targeted therapy | |||||||
| YES | 6 | (20.7) | 11 | (37.9) | 17 | (29.3) | 0.15 |
| NO | 23 | (79.3) | 18 | (62.1) | 41 | (70.7) | |
| Number of cures, | |||||||
| ≤ 6 | 17 | (58.6) | 19 | (65.5) | 28 | (48.3) | 0.56 |
| > 6 | 11 | (37.9) | 9 | (31.0) | 28 | (48.3) | |
| Missing data | 1 | (3.5) | 1 | (3.5) | 2 | (3.4) | |
| KRAS status | |||||||
| WT | 7 | (24.1) | 10 | (34.5) | 17 | (29.3) | 0.74 |
| Mutated | 12 | (41.4) | 14 | (48.3) | 26 | (44.8) | |
| Missing data | 10 | (34.5) | 5 | (17.2) | 15 | (25.9) | |
| Histological response | |||||||
| Blazer score* | |||||||
| 1 | 18 | (62.0) | 9 | (31.0) | 27 | (46.6) | 0.029 |
| 2 | 10 | (34.5) | 17 | (58.6) | 27 | (46.6) | |
| Missing data | 1 | (3.5) | 3 | (10.4 | 4 | (6.8) | |
| TRG** | |||||||
| 2 | 6 | (20.7) | 1 | (3.5) | 7 | (12.0) | 0.017 |
| 3 | 12 | (41.3) | 5 | (17.2) | 17 | (29.3) | |
| 4 | 10 | (34.5) | 19 | (65.5) | 29 | (50.0) | |
| 5 | 0 | (0.0) | 1 | (3.5) | 1 | (1.7) | |
| Missing data | 1 | (3.5) | 3 | (10.3) | 4 | (7.0) | |
* Blazer score (1 = major response: 1–49% of residual cancer cells; and 2 = minor response: ≥50% of residual cancer cells).**TRG = scoring system based on the presence of residual tumor cells and fibrosis extent.*** Chi-square or Fisher’s exact test